Mangoceuticals, Inc.
MGRX Nasdaq· Services-Misc Health & Allied Services, Nec
Last close · Oct 26, 2026
$0.24
KIRA · Stoqly’s AI analyst, in plain words
- Mangoceuticals, Inc. had $0.5M of revenue in fiscal 2025, down 26.0% on the year before.
- Its operating margin was −3,954.5%, down 2,660.1 pts: of every 100 in sales, about −3,954 is left after running the business.
- Mangoceuticals, Inc. lost $20.6M in fiscal 2025.
Market cap
$4.2M
P/E
—
Revenue
$0.5M
Net income
−$20.6M
Free cash flow
—
Operating margin
−3,954.5%
Mangoceuticals, Inc. in 30 seconds · fiscal 2025
Are sales growing?
−26.0%
No. Sales fell 26.0% last year.
Does it make a profit?
−4,527.0%
No. It lost money last year.
How healthy are the accounts?
2 / 8
Weak. It passes 2 of 8 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Mangoceuticals, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Apr 1, 2026
- Legal name
- MANGOCEUTICALS, INC.
- CIK
- 0001938046
Mangoceuticals, Inc. · MGRX
Results and finances
The last 4 fiscal years. Amounts in USD.
| Fiscal year | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|
| Sales and profit | ||||
| Revenue | $0.0M | $0.7M | $0.6M | $0.5M |
| Revenue growth | — | 8,119.1% | −15.8% | −26.0% |
| Gross margin | 55.1% | 59.0% | 61.7% | 54.9% |
| Operating margin | −22,377.5% | −1,260.3% | −1,294.4% | −3,954.5% |
| Net income | −$2.0M | −$9.2M | −$8.7M | −$20.6M |
| Net margin | −22,450.6% | −1,259.4% | −1,413.6% | −4,527.0% |
| Diluted EPS | −$0.19 | −$8.58 | −$4.80 | −$2.17 |
| Cash | ||||
| Cash from operations | −$1.3M | −$7.0M | −$4.9M | −$5.9M |
| Capital expenditure | $0.0M | $0.0M | — | — |
| Free cash flow | −$1.4M | −$7.0M | — | — |
| FCF margin | −15,613.5% | −957.1% | — | — |
| Share count change | — | −90.1% | 84.2% | 408.9% |
| Debt and strength | ||||
| Cash and short-term investments | $0.7M | $0.7M | $0.1M | $1.5M |
| Shareholders' equity | $0.6M | $0.8M | $13.9M | $15.2M |
| Current ratio | 2.7x | 4.0x | 0.1x | 1.7x |
| Interest coverage | −306.4x | — | −581.9x | −174.2x |
| Returns and quality | ||||
| Return on equity | −325.4% | −1,326.7% | −118.3% | −141.6% |
| Return on tangible equity | −325.4% | −1,189.0% | — | −2,254.0% |
| Piotroski F-score | — | 5 | 3 | 2 |
| Altman Z'' | −15.4 | −86.9 | 2.0 | 2.4 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.2M
2 insiders
Of sales under plans
0%
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Mangoceuticals, Inc. · MGRX
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $0.24 a share, the company is worth $4.2M.
Source: SEC EDGAR XBRL filings (CIK 0001938046). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.